Loading
A phase 2 trial of AAA617 in prostate cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC is a phase 2 interventional study registered as NCT05849298 by Novartis Pharmaceuticals, with 49 participants enrolled, started 2024-01-03 and due to reach its primary completion in 2026-12-23. Interventions recorded: AAA617, AAA517, Piflufolastat F 18, ARPI and ADT.
Shares Advanced Accelerator Applications (Novartis), Prostate cancer and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Prostate cancer and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Prostate cancer and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.